leisure time -WSS

leisure time

author：knowledge 2025-08-11 09:49:52 - browse：7597

The Novartis booth at ESMO in Madrid. — The Novartis booth at ESMO 2023 in Madrid. Andrew Joseph/STAT

MADRID — Results presented Monday could expand the use of a Novartis therapy for metastatic prostate cancer, moving it from a treatment used after chemotherapy to one with demonstrated benefits beforehand as well.

The Phase 3 data, highlighted in a prime session here at the annual meeting of the European Society for Medical Oncology, also amount to another win for cancer therapies designed to deliver radiation directly to tumor cells. It’s a field that Novartis has poured investments into, and that is attracting interest from other pharma companies.

The trial, called PSMAfore, enrolled patients with a type of metastatic prostate cancer whose disease had started to progress after taking a drug known as an androgen receptor pathway inhibitor, or ARPI. Patients were randomized to either receive a different ARPI or Novartis’ therapy, Pluvicto.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Paxlovid study fails to answer questions over benefit for broader groups

focus

WSS

Colonoscopy at 40? Study finds a possible benefit

Cloning humans is technically possible. It's curious no one has tried

Listen: Who gets the credit for GLP

STAT's guide to the next generation of CAR

Obesity experts on risks of Wegovy, Ozempic weight loss drugs

Ask STAT: What do you want to know about ChatGPT in medicine?

focus

leisure time

focus

Psychedelics group wrestles with new pharma identity

What would happen to your eyes if you looked at the solar eclipse?

Heart attack and stroke risk calculators need revising

Ask STAT: What do you want to know about ChatGPT in medicine?

Dobbs anniversary: the lost opportunity of abortion as health care

Would Medicare drug price negotiations stall in a shutdown?

After affirmative action ruling, medical educators look to 'holistic review'

What would happen to your eyes if you looked at the solar eclipse?

After affirmative action ruling, medical educators look to 'holistic review'

FDA grants conditional OK to Sarepta’s gene therapy for Duchenne

hotspot

Colonoscopy at 40? Study finds a possible benefit

How the Dana

The science behind Janet Jackson's pregnancy at 49

Sudafed saga points to U.S. issues with evaluating older drugs

Death of patient in Alzheimer’s trial raises question of possible risks

Study: Lilly Alzheimer's therapy slowed patients' cognitive decline

focus

focus

knowledge

explore